Current Understanding and Management of Giant Cell Arteritis and Polymyalgia Rheumatica Parasar Ghosh; Frances A Borg; Bhaskar Dasgupta Disclosures Expert Rev Clin Immunol. 2010;6 (6):913-928. 0 ...

Both polymyalgia rheumatica (PMR) and giant cell arteritis (GCA) present with a broad spectrum of clinical manifestations and almost exclusively occur in the population aged over 50 years. After ...

Causes of Giant Cell Arteritis (Temporal Arteritis):Giant Cell Arteritis is an autoimmune disorder where the immune system mistakenly attacks healthy blood vessels, leading to inflammation. While ...

Dr. Kimberly Trotter distilled four high-impact disease clusters—gout, rheumatoid arthritis (RA), systemic lupus ...

Objective: To investigate the relation between temporal artery biopsy (TAB) length and diagnostic sensitivity for giant cell arteritis. Methods: Histological TAB reports generated from four hospital ...

The genetic basis of giant cell arteritis is not fully understood but may play a role in treatment resistance and increased risk of ischaemic complications, including permanent vision loss. We present ...

NAION risk is most significant within the first 12 months of beginning semaglutide, and is highest in patients with additional risk factors.

Cosentyx missed its main goal in a Phase 3 GCA study, but showed lower steroid use. Novartis plans full review of the trial ...

A common medication already used for autoimmune diseases such as rheumatoid arthritis is effective for patients with giant ...

“While the phase 3 results of GCAptAIN did not replicate the positive outcomes observed in the phase 2 trial, we remain committed to continuing to drive scientific progress and deepening the ...

A common medication already used for autoimmune diseases such as rheumatoid arthritis is effective for patients with giant ...

Novartis (NYSE:NVS) (OTCPK:NVSEF) announced Thursday that its FDA-approved anti-inflammatory agent Cosentyx failed to reach ...